Inquest Links Death of 19-Year-Old California Law Student in London to Tirzepatide

A coroner in London concluded that the sudden death of 19-year-old Josephine Nasr, a California law student studying abroad, was caused by a cardiac arrhythmia triggered by an electrolyte imbalance from hypoglycemia. The inquest linked this chain of events to the weight-loss drug Tirzepatide, which she had been prescribed in the US. Nasr was found dead in her dorm room at the University of East London in September 2025, just one week after returning from a visit to her family in Corona, California. While she had a congenital heart condition known as myocardial bridging, the coroner determined that the drug-induced vomiting led to the fatal imbalance. This case adds to growing scrutiny of GLP-1 medications, though the coroner noted Nasr was otherwise healthy.
Key points
- Josephine Nasr, 19, died of a cardiac arrhythmia in her London dorm room on September 23, 2025.
- Coroner Graeme Irvine concluded the death resulted from an electrolyte imbalance caused by hypoglycemia, which stemmed from Tirzepatide-induced vomiting.
- Nasr had a congenital heart condition called myocardial bridging, which was exacerbated by the physiological stress of the imbalance.
- An empty vial of Tirzepatide was found in her room by university staff who discovered her body.
- Nasr had been prescribed the drug by a doctor in California while studying at the University of East London.
- She had reported nausea and vomiting to her family earlier that evening before losing consciousness.
Background
This inquest follows a period of increased regulatory attention to GLP-1 weight-loss drugs in the UK. In early August 2026, the UK Medicines and Healthcare products Regulatory Agency (MHRA) reported approximately 200 deaths linked to these medications, including 120 associated with tirzepatide. While the regulator emphasized that these reports do not prove causation and that the drugs are generally safe for most users, the Nasr case highlights specific risks for individuals with underlying cardiac conditions. The inquest underscores the importance of monitoring side effects like severe vomiting, which can lead to dangerous metabolic shifts in patients with pre-existing heart issues.
Why it matters
The Nasr case provides a concrete example of how GLP-1 drugs can interact with pre-existing health conditions to cause fatal outcomes. It highlights the critical need for careful patient screening and monitoring, particularly for those with undiagnosed or congenital heart issues. As these medications become increasingly popular for weight management, this inquest serves as a reminder that 'otherwise healthy' individuals can still face severe risks if underlying conditions are not properly considered during treatment.
What to watch
Regulators and medical professionals may review the inquest findings to assess if current prescribing guidelines adequately address the risks of electrolyte imbalances in patients with cardiac conditions. Families of other individuals who died after taking GLP-1 drugs may also seek similar reviews. The case could influence future safety warnings or prescribing practices for Tirzepatide and similar medications.
Want the full story? Read the original reporting
Read on New York Post